Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN:
1312-773X (Online)
Issue:
2025, vol. 31, issue1
Subject Area:
Medicine
-
DOI:
10.5272/jimab.2025311.5951
Published online: 14 January 2025
Original article
J of IMAB. 2025 Jan-Mar;31(1):5951-5955
METABOLIC AND CARDIOVASCULAR COMORBIDITIES IN BULGARIAN PATIENTS WITH CHRONIC VIRAL B AND C HEPATITIS
Radoslava Tsrancheva


, Dimitar Stoyanov
, Maria Stancheva
, Rozita Karakasheva
, Blagovest Stoimenov
, Ralitsa Pancheva
, Svilen Donev
, Ventseslav Yordanov
, Nikola Stanchev
, Ventsislava Pencheva
, Diana Stefanova-Petrova
,
Department of Propaedeutics of Internal Diseases, UMHAT "Alexandrovska"; Medical Faculty, Medical University - Sofia, Bulgaria.
ABSTRACT:
Recent epidemiologic data on chronic viral B and C hepatitis in Bulgaria are limited.The evolution of these infections depends on liver complications and the presence of nonliver comorbidities. The aim of the study was to assess the frequencies of arterial hypertension, ischemic heart disease, myocardial infarction, chronic heart failure, type 2 diabetes mellitus and metabolic syndrome in patients with chronic viral B and C hepatitis, associated liver cirrhosis and to compare with those of uninfected controls.
Material/Methods: We conducted a retrospective cross-sectional study in the period 2003-2023. We included 1803 patients, 474 with chronic hepatitis B, 482 with chronic hepatitis C and 847 uninfected controls. The patient's medical records were analyzed for the presence of arterial hypertension, ischemic heart disease, myocardial infarction, chronic heart failure, type 2 diabetes mellitus and metabolic syndrome.
Results: The most common comorbidity in the three groups was arterial hypertension, followed by type 2 diabetes mellitus. The frequency increased in chronically infected patients with liver cirrhosis. We observed a higher prevalence of myocardial infarctions in the patients with chronic hepatitis C (p=0.045) and of metabolic syndrome in the hepatitis B group (p=0.028). A higher prevalence of ischemic heart disease was observed in the group with chronic hepatitis B and liver cirrhosis (p=0.01).
Conclusions: Chronic hepatitis B and C in our groups were associated with significant morbidity, particularly with arterial hypertension and type 2 diabetes mellitus. The finding was more pronounced in patients with already developed liver cirrhosis.
Keywords: chronic hepatitis B, chronic hepatitis C, comorbidities,
- Download FULL TEXT /PDF 493 KB/
Please cite this article as: Tsrancheva R, Stoyanov D, Stancheva M, Karakasheva R, Stoimenov B, Pancheva R, Donev S, Yordanov V, Stanchev N, Pencheva V, Stefanova-Petrova D. Metabolic and cardiovascular comorbidities in Bulgarian patients with chronic viral B and C hepatitis. J of IMAB. 2025 Jan-Mar;31(1):5951-5955. [Crossref - 10.5272/jimab.2025311.5951]
Correspondence to: Radoslava Tsrancheva, Department of Propaedeutics of Internal diseases, UMHAT "Alexandrovska"; Medical Faculty, Medical University – Sofia; 1, St. Georgi Sofiiski Blvd., 1431 Sofia, Bulgaria; E-mail: tsrancheva@yahoo.com
REFERENCES:
1. Global hepatitis report 2024: action for access in low- and middle-income countries. WHO. 9 April 2024. [Internet]
2. Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, et al. An aging population of chronic hepatitis B with increasing comorbidities: A Territory-Wide Study From 2000 to 2017. Hepatology. 2020 Feb;71(2):444-455. [Crossref]
3. Xie J, Wang X, Pan D, Liu J, Li J, Gu J. Ageing and nonliver comorbidities in population with chronic hepatitis B infection in the western pacific region from 1990 to 2019. Front Physiol. 2023 May 18;14:1176113. [Crossref]
4. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. [PubMed]
5. Atanasova MV, Haydouchka IA, Zlatev SP, Stoilova YD, Iliev YT, Mateva NG. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. Minerva Gastroenterol Dietol. 2004 Mar;50(1):89-96. [PubMed]
6. Sperle I, Nielsen S, Gassowski M, Naneva Z, Perchemlieva T, Amato-Gauci A, et al. Prevalence of hepatitis C in the adult population of Bulgaria: a pilot study. BMC Res Notes. 2020 Jul 7;13(1):326. [PubMed]
7. Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, et al. Global burden of cardiovascular diseases and risks collaboration, 1990-2021. J Am Coll Cardiol. 2022 Dec 20;80(25):2372-2425. [PubMed]
8. Pancheva R, Runev N, Manov E, Dimchovski E, Stoimenov B, Kolev V, et al. Which patients with heart failure and preserved ejection fraction in Bulgaria are more likely to be rehospitalized and have higher mortality rate? Acta Med Mediterr. 2019; 35:2575. [Crossref]
9. Diabetes in Bulgaria. IDF. 2021. [Internet]
10. Causes of death statistics. Eurostat, Statistics Explained. March 2024. [Internet]
11. Cooper CL, Galanakis C, Donelle J, Kwong J, Boyd R, Boucher L, et al. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019 Aug 23;19(1):712. [Crossref]
12. Patmore LA, Katwaroe WK, van der Spek D, Choi HSJ, Patel K, Brakenhoff S, et al. Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2023 Nov;21(12):3089-3096. [PubMed]
13. Rajewski P, Zarębska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M, et al. Hepatitis C infection as a risk factor for hypertension and cardiovascular diseases: An EpiTer multicenter study. J Clin Med. 2022 Sep 1;11(17):5193. [PubMed]
14. Souza GHPE, Silva LD, Vieira DA, Rocha GA, Lima AS, Vidigal PVT. High-density lipoprotein cholesterol and systemic arterial hypertension are associated with hepatic necroinflammatory activity in patients with chronic hepatitis C. Arq Gastroenterol. 2023 Jul-Sep;60(3):287-299. [Crossref]
15. Toma L, Mercan-Stanciu A, Zgura A, Bacalbasa N, Diaconu C, Iliescu L. Evolution of arterial hypertension in patients with hepatitis C virus cirrhosis after antiviral treatment. IJAM. 2020 Sep;7(9):1302-1306. [Crossref]
16. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007 Oct;120(10):829-34. [PubMed]
17. Antonov K, Jelev D, Ivanova R, Alexiev A, Dragneva S, Mateva L. Metabolic face of chronic hepatitis B and C in Bulgaria. J of IMAB. 2011; 17(1):193-196. [Crossref]
18. van der Spek DPC, Katwaroe WK, van Kleef LA, Brakenhoff S, de Man RA, de Knegt RJ, et al. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020. Eur J Intern Med. 2023 Jan;107:86-92. [PubMed]
19. Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Nonalcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018 Sep;12(5):438-446. [PubMed]
20. Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond). 2007 May;31(5):871-5. [PubMed]
21. van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021 Aug 8;3(5):100350. [PubMed]
22. Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, et al. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002. [PubMed]
23. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxi A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology. 2016 Jan; 150(1):145-155.e4; [PubMed]
24. Lu MC, Wu YH, Chung CH, Lin HH, Hsieh TY, Chen PJ et al. Association of hepatitis B and C virus with the risk of coronary artery disease and cerebrovascular disease in patients with hepatocellular carcinoma. J Clin Med. 2023 Mar;12(7):2602. [Crossref]
Received: 22 July 2024
Published online: 14 January 2025
back to Online Journal